Novel Therapies for Multiple Myeloma
Highlights for the Oncology Nurse

Thursday, September 10, 2020 | 5:00 – 6:00 PM EDT
    LIVE Virtual Symposium

    Participants can access this live virtual event on Thursday, September 10, 2020 from 5:00 PM – 6:00 PM EDT.

    Activity Overview

    Many patients have misunderstandings and fears about participating in a clinical trial. Oncology nurses are in a key position to provide information in order to address patient's concerns and dispel myths. This interactive session will discuss novel therapies for multiple myeloma (MM), and deliver clinical pearls that can be applied in daily practice when discussing clinical trial participation with patients.

    • Sandra E. Kurtin, PhD, ANP-C, AOCN
      Director, Advanced Practice
      Assistant Professor of Clinical Medicine
      Assistant Professor of Nursing
      The University of Arizona Cancer Center
      Tucson, Arizona
    • Patricia Mangan, MSN, CRNP, APRN,BC
      Nurse Lead
      Hematologic Malignancies Program
      Abramson Cancer Center
      University of Pennsylvania
      Philadelphia, Pennsylvania
    • Charise Gleason, MSN, NP-BC, AOCNP
      Advanced Practice Provider Chief
      The Winship Cancer Institute of Emory University
      Adjunct Faculty Nell Hodgson Woodruff School of Nursing
      Atlanta, Georgia
    Program Thursday, September 10, 2020
    • 5:00 PM
    • Welcome and Introductions
    • 5:05 PM
    • Novel and Emerging Therapies for Multiply Relapsed Patients
    • 5:15 PM
    • Panel Discussion: Key Components in Communicating About Medication Adherence and Supportive Care
    • 5:20 PM
    • Emerging Immunotherapies for Multiple Myeloma
    • 5:30 PM
    • Panel Discussion: Communicating With Your Patient About Immunotherapies
    • 5:35 PM
    • Clinical Trials: Dispelling the Myths
    • 5:45 PM
    • Panel Discussion: Communicating With Your Patient About Clinical Trials
    • 5:55 PM
    • Q&A and Concluding Remarks
    Learning Objectives
    • Have increased knowledge regarding the
      • Risk factors for developing relapsed/refractory (R/R) MM
      • Potential adverse effects of novel and emerging therapies
    • Have greater competence related to
      • Discussing clinical trial participation with patients
    • Demonstrate greater confidence in their ability to
      • Provide education about novel therapies to patients
    Target Audience
    Goal Statement
    Credits Available
    • 1.0
    • For Nurses
    Accreditation Statement
    Supported by independent educational grants from
    Karyopharm Therapeutics
    Sanofi Genzyme